

Markus Munder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9549902/publications.pdf>

Version: 2024-02-01

81
papers

5,776
citations

147801

31
h-index

76900

74
g-index

83
all docs

83
docs citations

83
times ranked

8738
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766. | 27.0 | 1,246 |
| 2 | Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages. <i>Frontiers in Immunology</i> , 2014, 5, 532. | 4.8 | 868 |
| 3 | Arginase: an emerging key player in the mammalian immune system. <i>British Journal of Pharmacology</i> , 2009, 158, 638-651. | 5.4 | 589 |
| 4 | Suppression of T-cell functions by human granulocyte arginase. <i>Blood</i> , 2006, 108, 1627-1634. | 1.4 | 341 |
| 5 | Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. <i>Blood</i> , 2005, 105, 2549-2556. | 1.4 | 283 |
| 6 | Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?. <i>Trends in Immunology</i> , 2009, 30, 522-530. | 6.8 | 237 |
| 7 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264. | 13.7 | 187 |
| 8 | Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. <i>European Journal of Immunology</i> , 2007, 37, 935-945. | 2.9 | 150 |
| 9 | Characterization of a Novel Population of Low-Density Granulocytes Associated with Disease Severity in HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e48939. | 2.5 | 111 |
| 10 | Regulation of NK Cell Function by Human Granulocyte Arginase. <i>Journal of Immunology</i> , 2009, 182, 5259-5267. | 0.8 | 106 |
| 11 | Local Suppression of T Cell Responses by Arginase-Induced L-Arginine Depletion in Nonhealing Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e480. | 3.0 | 90 |
| 12 | Depletion of L-arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes. <i>Autophagy</i> , 2012, 8, 1557-1576. | 9.1 | 68 |
| 13 | Characterization of Neutrophil Subsets in Healthy Human Pregnancies. <i>PLoS ONE</i> , 2014, 9, e85696. | 2.5 | 67 |
| 14 | L-Arginine deprivation impairs Leishmania major-specific T cell responses. <i>European Journal of Immunology</i> , 2009, 39, 2161-2172. | 2.9 | 63 |
| 15 | Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. <i>Haematologica</i> , 2015, 100, 964-969. | 3.5 | 62 |
| 16 | Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 1. | 6.2 | 57 |
| 17 | Arginase Activity - A Marker of Disease Status in Patients with Visceral Leishmaniasis in Ethiopia. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2134. | 3.0 | 56 |
| 18 | Monocyte Dependent Regulation of Autoimmune Inflammation. <i>Current Molecular Medicine</i> , 2009, 9, 23-29. | 1.3 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes. <i>International Immunology</i> , 2012, 24, 303-313. | 4.0 | 54 |
| 20 | Macrophage: SHIP of Immunity. <i>Frontiers in Immunology</i> , 2014, 5, 620. | 4.8 | 54 |
| 21 | Phenotypic Alteration of Neutrophils in the Blood of HIV Seropositive Patients. <i>PLoS ONE</i> , 2013, 8, e72034. | 2.5 | 54 |
| 22 | Local Increase of Arginase Activity in Lesions of Patients with Cutaneous Leishmaniasis in Ethiopia. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1684. | 3.0 | 52 |
| 23 | Induced arginine transport via cationic amino acid transporter ¹ is necessary for human T ^H 1 cell proliferation. <i>European Journal of Immunology</i> , 2016, 46, 92-103. | 2.9 | 51 |
| 24 | Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression. <i>Frontiers in Immunology</i> , 2017, 8, 864. | 4.8 | 50 |
| 25 | Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e1977. | 3.0 | 48 |
| 26 | Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , 2020, 34, 1853-1865. | 7.2 | 47 |
| 27 | Highly Efficient Expansion of Human CD4+CD25+ Regulatory T Cells for Cellular Immunotherapy in Patients with Graft-Versus-Host Disease. <i>Journal of Immunotherapy</i> , 2006, 29, 336-349. | 2.4 | 41 |
| 28 | A Role for Toll-Like Receptor Mediated Signals in Neutrophils in the Pathogenesis of the Anti-Phospholipid Syndrome. <i>PLoS ONE</i> , 2012, 7, e42176. | 2.5 | 39 |
| 29 | Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions. <i>Frontiers in Immunology</i> , 2016, 7, 517. | 4.8 | 39 |
| 30 | Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. <i>Leukemia</i> , 2022, 36, 885-888. | 7.2 | 38 |
| 31 | Low Levels of Prothrombin Time (INR) and Platelets Do Not Increase the Risk of Significant Bleeding when Placing Central Venous Catheters*. <i>Medizinische Klinik</i> , 2009, 104, 331-335. | 0.3 | 37 |
| 32 | Age-Related Alteration of Arginase Activity Impacts on Severity of Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e235. | 3.0 | 35 |
| 33 | Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115. | 17.0 | 32 |
| 34 | Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability. <i>Frontiers in Oncology</i> , 2019, 9, 1268. | 2.8 | 30 |
| 35 | Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN- γ , but not IL-10 Production. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004468. | 3.0 | 28 |
| 36 | Quiescent and activated mouse granulocytes do not express granzyme A and B or perforin: similarities or differences with human polymorphonuclear leukocytes?. <i>Blood</i> , 2005, 106, 2871-2878. | 1.4 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Cytotoxicity of Tumor Antigen Specific Human T Cells Is Unimpaired by Arginine Depletion. PLoS ONE, 2013, 8, e63521. | 2.5 | 27 |
| 38 | Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia, 2021, 35, 2602-2615. | 7.2 | 27 |
| 39 | Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 2019, 19, 504. | 2.6 | 25 |
| 40 | Effect of ABC transporter expression and mutational status on survival rates of cancer patients. Biomedicine and Pharmacotherapy, 2020, 131, 110718. | 5.6 | 21 |
| 41 | Novel immunotherapies in multiple myeloma – chances and challenges. Haematologica, 2021, 106, 2555-2565. | 3.5 | 21 |
| 42 | Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial.. Journal of Clinical Oncology, 2020, 38, 8508-8508. | 1.6 | 21 |
| 43 | Protein energy malnutrition increases arginase activity in monocytes and macrophages. Nutrition and Metabolism, 2014, 11, 51. | 3.0 | 20 |
| 44 | Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes. Frontiers in Immunology, 2020, 11, 617699. | 4.8 | 19 |
| 45 | Granulocyte functions are independent of arginine availability. Journal of Leukocyte Biology, 2014, 96, 1047-1053. | 3.3 | 16 |
| 46 | Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers, 2020, 12, 2322. | 3.7 | 15 |
| 47 | SAMHD1 in cancer: curse or cure?. Journal of Molecular Medicine, 2022, 100, 351-372. | 3.9 | 15 |
| 48 | Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica, 2016, 101, e485-e487. | 3.5 | 14 |
| 49 | The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncolimmunology, 2018, 7, e1486356. | 4.6 | 14 |
| 50 | Human eosinophil granulocytes do not express the enzyme arginase. Journal of Leukocyte Biology, 2010, 87, 1125-1132. | 3.3 | 13 |
| 51 | Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites. PLoS Neglected Tropical Diseases, 2017, 11, e0005727. | 3.0 | 13 |
| 52 | Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British Journal of Haematology, 2021, 193, 561-569. | 2.5 | 10 |
| 53 | Role of arginase in asthma: potential clinical applications. Expert Review of Clinical Pharmacology, 2010, 3, 17-23. | 3.1 | 8 |
| 54 | Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. Blood Cancer Journal, 2019, 9, 45. | 6.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Teaming up for CAR-T cell therapy. <i>Haematologica</i> , 2019, 104, 2335-2336. | 3.5 | 7 |
| 56 | Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. <i>BMC Cancer</i> , 2020, 20, 245. | 2.6 | 7 |
| 57 | Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. <i>Leukemia</i> , 2021, 35, 809-822. | 7.2 | 7 |
| 58 | Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 13. | 6.2 | 6 |
| 59 | 133p53 Δ enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity. , 2021, 9, e001846. | | 6 |
| 60 | Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. <i>Leukemia</i> , 2019, 33, 258-261. | 7.2 | 5 |
| 61 | Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. <i>Leukemia</i> , 2021, 35, 3007-3011. | 7.2 | 4 |
| 62 | Lethal systemic and brain infection caused by <i>Prototheca zopfii</i> algae in a patient with acute myeloid leukemia. <i>Medical Mycology Case Reports</i> , 2021, 32, 17-20. | 1.3 | 4 |
| 63 | Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8036-8036. | 1.6 | 4 |
| 64 | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. <i>Cancers</i> , 2021, 13, 4856. | 3.7 | 3 |
| 65 | GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy. <i>Blood</i> , 2013, 122, 3369-3369. | 1.4 | 3 |
| 66 | Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 2 |
| 67 | Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 1328-1341. | 2.9 | 2 |
| 68 | Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4233-4233. | 1.4 | 2 |
| 69 | Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial. <i>Blood</i> , 2016, 128, 3373-3373. | 1.4 | 2 |
| 70 | Interfering with Arginine Metabolism As a New Treatment Strategy for Multiple Myeloma. <i>Blood</i> , 2015, 126, 3005-3005. | 1.4 | 2 |
| 71 | Arginine Depletion in Combination with Canavanine Supplementation Induces Massive Cell Death in Myeloma Cells By Interfering with Their Protein Metabolism and Bypassing Potential Rescue Mechanisms. <i>Blood</i> , 2018, 132, 3205-3205. | 1.4 | 2 |
| 72 | Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer Patients. <i>Cells</i> , 2020, 9, 299. | 4.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial. <i>Blood</i> , 2014, 124, 3475-3475. | 1.4 | 1 |
| 74 | Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR. <i>Journal of Clinical Oncology</i> , 2019, 37, 8040-8040. | 1.6 | 1 |
| 75 | GCN2 Kinase: An Evolutionarily Conserved Mechanism of Human T Lymphocyte Suppression Upon Arginine Depletion. <i>Clinical Immunology</i> , 2007, 123, S113. | 3.2 | 0 |
| 76 | Response After Induction Therapy in Transplant-eligible Newly-diagnosed Myeloma - a Pooled Analysis from Three Subsequent Multicenter Phase III Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e76. | 0.4 | 0 |
| 77 | Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e43. | 0.4 | 0 |
| 78 | Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e208. | 0.4 | 0 |
| 79 | Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients. <i>Blood</i> , 2009, 114, 3400-3400. | 1.4 | 0 |
| 80 | Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial. <i>Blood</i> , 2013, 122, 1897-1897. | 1.4 | 0 |
| 81 | Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. <i>Blood</i> , 2014, 124, 4777-4777. | 1.4 | 0 |